Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Rini on the Results From His Axitinib and Sorafenib Trial

June 24th 2011

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

HER2 Signaling Beckons: Dimerization Process, Combination Therapies Highlight New Research

June 24th 2011

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

Dr. Infante on the Next Step in Melanoma Research

June 23rd 2011

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Dr. Kris Discusses the Pemetrexed Trial Results

June 23rd 2011

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Vismodegib Trial Yields Benefits in BCC patients

June 20th 2011

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

Hedgehog Pathway Inhibitor GDC-0449 Reduces Lesion Size in Patients With Basal Cell Carcinoma

June 20th 2011

Patients with basal cell carcinoma had an eightfold decrease in lesion area when treated with GDC-0449

Smart Moves? E-patient Systems Rise Amid Skepticism

June 16th 2011

During the past 20 years, disease management systems have mushroomed in medicine

Emerging Cancer Vaccines Appear to Be on Track for Major Advances

June 15th 2011

Both industry and clinical sources agree that cancer vaccine research is finally on the right track to achieve major advances in treatment.

Scientists Pioneer Technology to Detect More Chromosomal Aberrations in Cancer Tumors

June 14th 2011

The investigators developed a computer tool that is dramatically better for finding genetic missteps that promote cancer.

Dr. Paz-Ares Discusses Pemetrexed Clinical Trial

June 13th 2011

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial

University of Wisconsin Carbone Cancer Center: A Tradition of Comprehensive, Multidisciplinary Care

June 13th 2011

Currently, more than 250 physicians and scientists work in concert to provide state-of- the art diagnosis, treatment, and aftercare for the more than 20,000 patients seen each year at the UW hospitals, clinics, and affiliate clinical facilities

Dr. Chapman Describes the Vemurafenib Clinical Trial

June 10th 2011

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Dr. Vogelzang Discusses Cabozantinib Trial Design

June 9th 2011

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib Trial Design

Dr. Cella on Patient Assessment Reference Scores

June 5th 2011

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores

Molecular Profiling Boosts Targeted Therapies in Phase I Trial

June 4th 2011

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

Attacking the Frontiers of Breast Cancer: A Conversation With Joyce A. O'Shaughnessy, MD

June 3rd 2011

As a child Joyce Ann O'Shaughnessy enjoyed science and her home chemistry set. Still, she didn't give much thought to pursuing the subject beyond the confines of her school - until she faced a tragedy.

Experimental Melanoma Vaccine May Shrink Late-Stage Tumors

June 2nd 2011

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma

A Tale of 2 Complexes: The mTOR Signaling Pathway in Cancer Development

June 2nd 2011

The mammalian target of rapamycin (mTOR) is a master switch, central regulator, or key integrator of cell growth and proliferation

Fine-Tuning Cancer Care: NCCN Changes 11 Guidelines

June 1st 2011

Highlights on updates to the clinical practice guidelines from the annual National Comprehensive Cancer Network (NCCN) conference

Climbing to New Heights: James Berenson, MD, and the Institute for Myeloma and Bone Cancer Research

May 27th 2011

Oncologist James Berenson, MD, likes all of his patients, especially the ones with whom he skis.